Clinical Report: Global Prevalence and Risk Factors of Long COVID
Overview
This comprehensive meta-analysis of 429 studies found a global pooled long COVID prevalence of 36%, with the highest rates in South America at 51%. Key risk factors include being unvaccinated, infection with pre-Omicron variants, and female sex. Long COVID subtypes most commonly involve respiratory symptoms, general fatigue, psychological, and neurological manifestations.
Background
Long COVID, also known as postacute sequelae of COVID-19 (PASC), is a multisystemic syndrome occurring after SARS-CoV-2 infection, characterized by persistent or new symptoms lasting at least two months. Definitions vary, but the World Health Organization defines it as symptoms continuing or developing three months post-infection. The condition affects a significant proportion of COVID-19 survivors worldwide, with diverse symptom subtypes and risk factors. Understanding its global prevalence and associated factors is critical for managing this ongoing public health challenge.
Data Highlights
Parameter
Estimate
95% Confidence Interval
Number of Studies
Global Long COVID Prevalence
36%
33%–40%
144
South America Prevalence
51%
35%–66%
Not specified
Prevalence at <1 year follow-up
35%
31%–39%
Not specified
Prevalence at 1–2 years follow-up
46%
37%–57%
Not specified
Respiratory Subtype
20%
14%–28%
31
General Fatigue Subtype
20%
18%–23%
119
Psychological Subtype
18%
11%–28%
10
Neurological Subtype
16%
8%–30%
23
Unvaccinated Risk Factor OR
2.09
1.55–2.81
7
Pre-Omicron Variant Infection OR
1.74
1.40–2.17
6
Female Sex OR
1.56
1.32–1.84
33
Key Findings
Global pooled prevalence of long COVID is 36% among COVID-19 survivors.
South America shows the highest regional prevalence at 51%.
Long COVID prevalence persists and may increase over time, reaching 46% at 1–2 years post-infection.
Most common long COVID subtypes include respiratory symptoms (20%), general fatigue (20%), psychological symptoms (18%), and neurological symptoms (16%).
Strongest risk factors for developing long COVID are being unvaccinated (OR 2.09), infection with pre-Omicron variants (OR 1.74), and female sex (OR 1.56).
There is significant heterogeneity in prevalence estimates across populations, underscoring the need for standardized, globally representative studies.
Clinical Implications
Clinicians should recognize that over one-third of COVID-19 survivors globally may experience long COVID, with symptoms potentially persisting or emerging up to two years post-infection. Vaccination remains a critical preventive measure to reduce long COVID risk. Awareness of higher susceptibility in females and those infected with pre-Omicron variants can guide patient monitoring and management strategies.
Conclusion
Long COVID represents a prevalent and persistent global health challenge with diverse symptomatology and identifiable risk factors. Continued research using standardized definitions and representative cohorts is essential to improve understanding and care.
References
Worldwide Incidence of Long COVID, Its Variants, and Associated Risk Factors: A Comprehensive Systematic Review and Meta-Analysis
